CN104717980A - 干细胞增强疗法 - Google Patents

干细胞增强疗法 Download PDF

Info

Publication number
CN104717980A
CN104717980A CN201380053708.7A CN201380053708A CN104717980A CN 104717980 A CN104717980 A CN 104717980A CN 201380053708 A CN201380053708 A CN 201380053708A CN 104717980 A CN104717980 A CN 104717980A
Authority
CN
China
Prior art keywords
seq
antibody
incorporated
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380053708.7A
Other languages
English (en)
Chinese (zh)
Inventor
辛西娅·巴姆达德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/060684 external-priority patent/WO2013059373A2/en
Priority claimed from PCT/US2013/025981 external-priority patent/WO2013123084A1/en
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Priority to CN202010192670.3A priority Critical patent/CN111388664A/zh
Priority to CN201810110588.4A priority patent/CN108175856B/zh
Publication of CN104717980A publication Critical patent/CN104717980A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380053708.7A 2012-08-14 2013-08-14 干细胞增强疗法 Pending CN104717980A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010192670.3A CN111388664A (zh) 2012-08-14 2013-08-14 干细胞增强疗法
CN201810110588.4A CN108175856B (zh) 2012-08-14 2013-08-14 干细胞增强疗法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201261683155P 2012-08-14 2012-08-14
US61/683,155 2012-08-14
US201261684654P 2012-08-17 2012-08-17
US61/684,654 2012-08-17
US201261693712P 2012-08-27 2012-08-27
US61/693,712 2012-08-27
USPCT/US2012/060684 2012-10-17
PCT/US2012/060684 WO2013059373A2 (en) 2011-10-17 2012-10-17 Media for stem cell proliferation and induction
PCT/US2013/025981 WO2013123084A1 (en) 2012-02-13 2013-02-13 Method for detecting circulating fetal cells
USPCT/US2013/025981 2013-02-13
US201361837560P 2013-06-20 2013-06-20
US61/837,560 2013-06-20
PCT/US2013/055015 WO2014028668A2 (en) 2012-08-14 2013-08-14 Stem cell enhancing therapeutics

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202010192670.3A Division CN111388664A (zh) 2012-08-14 2013-08-14 干细胞增强疗法
CN201810110588.4A Division CN108175856B (zh) 2012-08-14 2013-08-14 干细胞增强疗法

Publications (1)

Publication Number Publication Date
CN104717980A true CN104717980A (zh) 2015-06-17

Family

ID=50101604

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201380053708.7A Pending CN104717980A (zh) 2012-08-14 2013-08-14 干细胞增强疗法
CN202010192670.3A Pending CN111388664A (zh) 2012-08-14 2013-08-14 干细胞增强疗法
CN201810110588.4A Active CN108175856B (zh) 2012-08-14 2013-08-14 干细胞增强疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010192670.3A Pending CN111388664A (zh) 2012-08-14 2013-08-14 干细胞增强疗法
CN201810110588.4A Active CN108175856B (zh) 2012-08-14 2013-08-14 干细胞增强疗法

Country Status (8)

Country Link
US (2) US9932407B2 (https=)
EP (1) EP2885000A4 (https=)
JP (4) JP6664219B2 (https=)
CN (3) CN104717980A (https=)
AU (2) AU2013302620B2 (https=)
CA (1) CA2882222A1 (https=)
IL (1) IL237228B (https=)
WO (1) WO2014028668A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
AU2015243948B2 (en) 2014-04-07 2020-10-15 Minerva Biotechnologies Corporation Anti-NME antibody
CN116199790A (zh) * 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
KR102486507B1 (ko) * 2016-04-08 2023-01-09 아이티아이 헬스, 인크. 플렉틴-1 결합 항체 및 그의 용도
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
JP7379347B2 (ja) * 2017-10-11 2023-11-14 ジィールバイオ，インコーポレーテッド プレクチン１結合抗体およびその使用
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN120484122A (zh) * 2019-01-11 2025-08-15 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
EP4161970A4 (en) 2020-06-08 2024-07-10 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES
CA3183682A1 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CN119317447A (zh) 2022-04-12 2025-01-14 米纳瓦生物技术公司 抗可变muc1*抗体及其用途
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020279A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
CN101652469A (zh) * 2006-12-06 2010-02-17 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
CN102272290A (zh) * 2008-10-09 2011-12-07 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
CN102549146A (zh) * 2009-06-11 2012-07-04 米纳瓦生物技术公司 用于培养干细胞和祖细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
JP2005508839A (ja) * 2001-03-29 2005-04-07 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ペプチドおよびｍｕｃ１タンパク質に対する抗体
WO2003089451A2 (en) * 2002-04-22 2003-10-30 Dyax Corporation Antibodies specific for mucin polypeptide
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
EP2526957A3 (en) 2005-03-30 2013-02-20 Minerva Biotechnologies Corporation Proliferation of MUC1 expressing cells
US7825092B2 (en) * 2006-08-08 2010-11-02 University Of South Florida Dendroaspis natriuretic peptide for treatment of cancer
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP3130607B1 (en) * 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
CN102264765B (zh) * 2008-10-28 2016-01-20 盐野义制药株式会社 抗muc1抗体
US8628959B2 (en) * 2009-05-23 2014-01-14 Incube Labs, Llc Methods for cancer treatment using stem cells
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020279A2 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
CN101652469A (zh) * 2006-12-06 2010-02-17 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
CN102272290A (zh) * 2008-10-09 2011-12-07 米纳瓦生物技术公司 用于在细胞中诱导多能性的方法
CN102549146A (zh) * 2009-06-11 2012-07-04 米纳瓦生物技术公司 用于培养干细胞和祖细胞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHERRY T. HIKITA，ET AL.: "MUC1* Mediates the Growth of Human Pluripotent Stem Cells", 《PLOS ONE》 *

Also Published As

Publication number Publication date
JP6757712B2 (ja) 2020-09-23
JP2015526446A (ja) 2015-09-10
AU2018220126B2 (en) 2020-07-23
IL237228B (en) 2021-03-25
CN108175856B (zh) 2024-01-26
EP2885000A4 (en) 2015-12-23
AU2013302620A1 (en) 2015-04-02
US20170121406A1 (en) 2017-05-04
AU2013302620B2 (en) 2018-08-02
EP2885000A2 (en) 2015-06-24
AU2018220126A1 (en) 2018-09-13
US20150299334A1 (en) 2015-10-22
JP2020109101A (ja) 2020-07-16
CA2882222A1 (en) 2014-02-20
JP6664219B2 (ja) 2020-03-13
CN108175856A (zh) 2018-06-19
JP2018070640A (ja) 2018-05-10
JP2022025136A (ja) 2022-02-09
US9932407B2 (en) 2018-04-03
CN111388664A (zh) 2020-07-10
IL237228A0 (en) 2015-04-30
WO2014028668A2 (en) 2014-02-20
WO2014028668A3 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
JP6757712B2 (ja) 幹細胞増強治療法
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
US10934358B2 (en) Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
CN101472948A (zh) 使用抗IL-1α抗体治疗癌症
KR102693317B1 (ko) 암 면역요법을 위한, 활성화되고 확장된 자연 킬러 세포와 조합된 항-cxcr4 항체
KR20250099286A (ko) Eltd1에 대한 단일클론성 항체 및 이의 용도
TW202430214A (zh) Cd47阻斷劑及抗bcma/抗cd3雙特異性抗體之組合療法
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
JP2021504492A (ja) 癌治療のための組成物および方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150617

RJ01 Rejection of invention patent application after publication